Alpha 2.0
Login Register
» Authors » Ann M Buchanan

Ann M Buchanan

Explore the profile of Ann M Buchanan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 284
Followers 0
Related Specialties
Infectious Diseases
Pediatrics
Pharmacology
Top 10 Co-Authors
Coleen K Cunningham
John A Crump
Cindy Vavro
Andrew Wiznia
Theodore Ruel
Edward P Acosta
Hardik Chandasana
Ellen Townley
Rajendra Singh
Dorothy E Dow
Published In
Lancet HIV
J Pediatric Infect Dis Soc
J Acquir Immune Defic Syndr
Trop Med Int Health
Pediatr Infect Dis J
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy and Safety of the Two-Drug Regimen Dolutegravir/Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-label, Phase 3b Trial
Puthanakit T, Aurpibul L, Lopez M, Wang M, Ciuffa M, Bontempo G, et al.
J Acquir Immune Defic Syndr . 2025 Feb; PMID: 39988749
Background: Dolutegravir/Lamivudine is recommended for initial antiretroviral therapy (ART) in adults living with HIV-1; however, no clinical trials have assessed this regimen in adolescents, a potentially more challenging population to...
2.
A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1
Chandasana H, Buchanan A, McKenna M, Brothers C, Hyatt S, Adkison K, et al.
J Clin Pharmacol . 2024 Sep; PMID: 39235061
In March 2022, the US Food and Drug Administration expanded indications of TRIUMEQ, a once-daily fixed-dose combination (FDC) containing abacavir (ABC), dolutegravir (DTG), and lamivudine (3TC) to include pediatric patients...
3.
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective
Buchanan A, Bekker A, Chandasana H, DeMasi R, Lulic Z, Ernest T, et al.
Int J Antimicrob Agents . 2024 Aug; 64(4):107306. PMID: 39146996
The HIV treatment landscape for adults has progressed dramatically in recent decades; however, paediatric populations continue to experience delayed and limited access to effective and safe antiretroviral therapy options. Despite...
4.
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics
Chandasana H, Hayes S, Buchanan A, Brothers C, Wiznia A, Bartlett M, et al.
AIDS . 2024 May; 38(9):F11-F18. PMID: 38768443
Objective: Dolutegravir (DTG) is a once-daily HIV-1 integrase inhibitor approved for the treatment of HIV-1 infection in adults and children from 4 weeks of age. The posology of DTG in...
5.
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study
Brooks K, Kiser J, Ziemba L, Ward S, Rani Y, Cressey T, et al.
Lancet HIV . 2023 Aug; 10(8):e506-e517. PMID: 37541705
Background: Child-friendly fixed-dose combination (FDC) antiretroviral therapy (ART) options are limited. We evaluated the pharmacokinetics, safety, and tolerability of dispersible and immediate-release FDC abacavir, dolutegravir, and lamivudine taken once per...
6.
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial
Ruel T, Acosta E, Liu J, Gray K, George K, Montanez N, et al.
Lancet HIV . 2022 Apr; 9(5):e332-e340. PMID: 35489377
Background: Safe and potent antiretroviral medications in child-friendly formulations are needed to treat young children living with HIV-1. We aimed to select dosing for a dispersible tablet formulation of dolutegravir...
7.
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children
Singh R, Adkison K, Baker M, Parasrampuria R, Wolstenholme A, Davies M, et al.
Pediatr Infect Dis J . 2021 Nov; 41(3):230-237. PMID: 34817414
Background: The World Health Organization (WHO) 2019 antiretroviral treatment guidelines recommend use of optimal treatment regimens in all populations. Dolutegravir-based regimens are the preferred first-line and second-line treatment in infants...
8.
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
Vavro C, Ruel T, Wiznia A, Montanez N, Nangle K, Horton J, et al.
Antimicrob Agents Chemother . 2021 Oct; 66(1):e0164521. PMID: 34694878
P1093 is a multicenter, open-label, phase I/II study of pharmacokinetics, safety, and tolerability of dolutegravir plus an optimized background regimen in pediatric participants aged 4 weeks to <18 years with...
9.
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study
Viani R, Ruel T, Alvero C, Fenton T, Acosta E, Hazra R, et al.
J Pediatric Infect Dis Soc . 2019 Apr; 9(2):159-165. PMID: 30951600
Background: P1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy...
10.
Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults
Singh R, Shaik J, Skoura N, Joshi S, Shreeves T, Casillas L, et al.
J Acquir Immune Defic Syndr . 2018 Sep; 79(5):631-638. PMID: 30239425
Background: The fixed-dose combination (FDC) tablet formulation of abacavir/dolutegravir/lamivudine is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing ≥40 kg. Alternative formulations with acceptable palatability...